{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:20Z","timestamp":1793662040520,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-021-00647-0","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T22:02:47Z","timestamp":1636408967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration"],"prefix":"10.1208","volume":"23","author":[{"given":"David","family":"Bussing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Ping","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwni","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"issue":"1","key":"647_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"RM Lu","year":"2020","unstructured":"Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.","journal-title":"J Biomed Sci"},{"issue":"1","key":"647_CR2","doi-asserted-by":"publisher","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","volume":"13","author":"H Kaplon","year":"2021","unstructured":"Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13(1):1860476.","journal-title":"MAbs"},{"key":"647_CR3","doi-asserted-by":"crossref","unstructured":"Bates A, Power CA. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies (Basel). 2019;8(2).","DOI":"10.3390\/antib8020028"},{"issue":"10200","key":"647_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804.","journal-title":"Lancet"},{"key":"647_CR5","doi-asserted-by":"crossref","unstructured":"Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired resistance to antibody-drug conjugates. Cancers (Basel). 2019;11(3).","DOI":"10.3390\/cancers11030394"},{"issue":"2","key":"647_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/d41573-020-00001-7","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19(2):79\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"647_CR7","unstructured":"FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies [press release]. U.S. Food and Drug Administration, December 20, 2019."},{"key":"647_CR8","unstructured":"FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments [press release]. U.S. Food and Drug Administration, April 22, 2020."},{"key":"647_CR9","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","volume":"11","author":"M Kalim","year":"2017","unstructured":"Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265\u201376.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"647_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015\u201335.","journal-title":"Adv Ther"},{"key":"647_CR11","volume-title":"Adler's physiology of the eye","author":"PL Kaufman","year":"2011","unstructured":"Kaufman PL, Alm A, Levin LA, Adler FH. Adler\u2019s physiology of the eye. 11th ed. London, New York: Saunders\/Elsevier; 2011.","edition":"11"},{"issue":"11","key":"647_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nri1224","volume":"3","author":"JW Streilein","year":"2003","unstructured":"Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879\u201389.","journal-title":"Nat Rev Immunol"},{"key":"647_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000099259","volume":"92","author":"P Zamiri","year":"2007","unstructured":"Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy. 2007;92:86\u201393.","journal-title":"Chem Immunol Allergy"},{"issue":"23","key":"647_CR14","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1002\/cncr.27622","volume":"118","author":"M Beeram","year":"2012","unstructured":"Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118(23):5733\u201340.","journal-title":"Cancer"},{"issue":"4","key":"647_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398\u2013405.","journal-title":"J Clin Oncol"},{"issue":"4","key":"647_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29(4):455\u201363.","journal-title":"J Immunother"},{"issue":"4","key":"647_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","volume":"21","author":"DS Borkar","year":"2013","unstructured":"Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21(4):1167\u201374.","journal-title":"Support Care Cancer"},{"issue":"3","key":"647_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/15569527.2011.636118","volume":"31","author":"FT Fraunfelder","year":"2012","unstructured":"Fraunfelder FT, Fraunfelder FW. Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol. 2012;31(3):195\u20137.","journal-title":"Cutan Ocul Toxicol"},{"issue":"10","key":"647_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589\u2013604.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"647_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, Inan S, Ozcan S, Dogan M, Kusbeci T, Yavas GF, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol. 2017;47(4):205\u201310.","journal-title":"Turk J Ophthalmol"},{"key":"647_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol. 2017;177:213\u201324.","journal-title":"Am J Ophthalmol"},{"key":"647_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","volume":"137","author":"EM del Amo","year":"2015","unstructured":"del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res. 2015;137:111\u201324.","journal-title":"Exp Eye Res"},{"issue":"1","key":"647_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0192623307310955","volume":"36","author":"BG Short","year":"2008","unstructured":"Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36(1):49\u201362.","journal-title":"Toxicol Pathol"},{"issue":"3","key":"647_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/1871527315666151110124957","volume":"15","author":"EY Zernii","year":"2016","unstructured":"Zernii EY, Baksheeva VE, Iomdina EN, Averina OA, Permyakov SE, Philippov PP, et al. Rabbit models of ocular diseases: new relevance for classical approaches. CNS Neurol Disord Drug Targets. 2016;15(3):267\u201391.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"3","key":"647_CR25","first-page":"325","volume":"147","author":"GC Robinson","year":"1993","unstructured":"Robinson GC, Jan JE. Acquired ocular visual impairment in children 1960\u20131989. Am J Dis Child. 1993;147(3):325\u20138.","journal-title":"Am J Dis Child."},{"issue":"12","key":"647_CR26","first-page":"1321","volume":"141","author":"GC Robinson","year":"1987","unstructured":"Robinson GC, Jan JE, Kinnis C. Congenital ocular blindness in children, 1945 to 1984. Am J Dis Child. 1987;141(12):1321\u20134.","journal-title":"Am J Dis Child"},{"issue":"Database issue","key":"647_CR27","doi-asserted-by":"publisher","first-page":"D793","DOI":"10.1093\/nar\/gkn665","volume":"37","author":"J Amberger","year":"2009","unstructured":"Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick\u2019s Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res. 2009;37(Database issue):D793-6.","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"647_CR28","doi-asserted-by":"publisher","first-page":"e0183837","DOI":"10.1371\/journal.pone.0183837","volume":"12","author":"MP Krebs","year":"2017","unstructured":"Krebs MP, Collin GB, Hicks WL, Yu M, Charette JR, Shi LY, et al. Mouse models of human ocular disease for translational research. PLoS One. 2017;12(8):e0183837.","journal-title":"PLoS One."},{"key":"647_CR29","doi-asserted-by":"publisher","first-page":"391384","DOI":"10.1155\/2011\/391384","volume":"2011","author":"J Won","year":"2011","unstructured":"Won J, Shi LY, Hicks W, Wang J, Hurd R, Naggert JK, et al. Mouse model resources for vision research. J Ophthalmol. 2011;2011:391384.","journal-title":"J Ophthalmol."},{"key":"647_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-62703-080-9_2","volume":"935","author":"B Chang","year":"2013","unstructured":"Chang B. Mouse models for studies of retinal degeneration and diseases. Methods Mol Biol. 2013;935:27\u201339.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"647_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1017\/S0952523805225075","volume":"22","author":"B Chang","year":"2005","unstructured":"Chang B, Hawes NL, Hurd RE, Wang J, Howell D, Davisson MT, et al. Mouse models of ocular diseases. Vis Neurosci. 2005;22(5):587\u201393.","journal-title":"Vis Neurosci"},{"key":"647_CR32","unstructured":"Herceptin(R). [package insert]. South San Fransisco, CA: Genentech, Inc. 1998."},{"issue":"10","key":"647_CR33","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1124\/dmd.119.087809","volume":"47","author":"Z Li","year":"2019","unstructured":"Li Z, Li Y, Chang HP, Chang HY, Guo L, Shah DK. Effect of size on solid tumor disposition of protein therapeutics. Drug Metab Dispos. 2019;47(10):1136\u201345.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"647_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","volume":"43","author":"AP Singh","year":"2016","unstructured":"Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43(6):567\u201382.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"647_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1124\/dmd.119.089276","volume":"48","author":"S Sharma","year":"2020","unstructured":"Sharma S, Li Z, Bussing D, Shah DK. Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells. Drug Metab Dispos. 2020;48(5):368\u201377.","journal-title":"Drug Metab Dispos"},{"key":"647_CR36","first-page":"e51936","volume":"92","author":"J Aerts","year":"2014","unstructured":"Aerts J, Nys J, Arckens L. A highly reproducible and straightforward method to perform in vivo ocular enucleation in the mouse after eye opening. J Vis Exp. 2014;92:e51936.","journal-title":"J Vis Exp."},{"key":"647_CR37","unstructured":"SimBiology. 6.0 ed. Natick, Massachusetts, United States: The MathWorks, Inc.; 2020."},{"issue":"1","key":"647_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1023\/A:1016255124336","volume":"12","author":"JR Nedelman","year":"1995","unstructured":"Nedelman JR, Gibiansky E, Lau DT. Applying Bailer\u2019s method for AUC confidence intervals to sparse sampling. Pharm Res. 1995;12(1):124\u20138.","journal-title":"Pharm Res"},{"key":"647_CR39","unstructured":"Microsft Excel. Office 365. Redmond, Washington, United States: Microsoft Corporation; 2020."},{"issue":"2","key":"647_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2):297\u2013305.","journal-title":"MAbs"},{"issue":"1","key":"647_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","volume":"8","author":"Z Li","year":"2016","unstructured":"Li Z, Krippendorff BF, Sharma S, Walz AC, Lave T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs. 2016;8(1):113\u20139.","journal-title":"MAbs"},{"issue":"4","key":"647_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/hyb.2011.0023","volume":"30","author":"T Kazemi","year":"2011","unstructured":"Kazemi T, Tahmasebi F, Bayat AA, Mohajer N, Khoshnoodi J, Jeddi-Tehrani M, et al. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma (Larchmt). 2011;30(4):347\u201353.","journal-title":"Hybridoma (Larchmt)"},{"key":"647_CR43","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.ebiom.2020.102996","volume":"60","author":"X Ding","year":"2020","unstructured":"Ding X, Gu W, Zhong Y, Hao X, Liu J, Xia S, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020;60:102996.","journal-title":"EBioMedicine."},{"issue":"6","key":"647_CR44","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1021\/acs.molpharmaceut.0c01218","volume":"18","author":"P Jakubiak","year":"2021","unstructured":"Jakubiak P, Alvarez-Sanchez R, Fueth M, Broders O, Kettenberger H, Stubenrauch K, et al. Ocular pharmacokinetics of intravitreally injected protein therapeutics: comparison among standard-of-care formats. Mol Pharm. 2021;18(6):2208\u201317.","journal-title":"Mol Pharm"},{"issue":"5","key":"647_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/019262339902700507","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536\u201344.","journal-title":"Toxicol Pathol"},{"issue":"12","key":"647_CR46","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1023\/A:1007657109012","volume":"17","author":"DW Drolet","year":"2000","unstructured":"Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000;17(12):1503\u201310.","journal-title":"Pharm Res"},{"issue":"2","key":"647_CR47","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726\u201333.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"647_CR48","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114(12):2179\u201382.","journal-title":"Ophthalmology"},{"issue":"5","key":"647_CR49","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855\u20139.","journal-title":"Ophthalmology"},{"issue":"10","key":"647_CR50","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1167\/iovs.08-3148","volume":"50","author":"H Nomoto","year":"2009","unstructured":"Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50(10):4807\u201313.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"647_CR51","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1167\/iovs.15-17108","volume":"56","author":"K Gadkar","year":"2015","unstructured":"Gadkar K, Pastuskovas CV, Le Couter JE, Elliott JM, Zhang J, Lee CV, et al. Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics. Invest Ophthalmol Vis Sci. 2015;56(9):5390\u2013400.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"647_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/OPTH.S19555","volume":"5","author":"CI Sinapis","year":"2011","unstructured":"Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol. 2011;5:697\u2013704.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"647_CR53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/19420862.2018.1473910","volume":"10","author":"HY Chang","year":"2018","unstructured":"Chang HY, Morrow K, Bonacquisti E, Zhang W, Shah DK. Antibody pharmacokinetics in rat brain determined using microdialysis. MAbs. 2018;10(6):843\u201353.","journal-title":"MAbs"},{"issue":"6","key":"647_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"647_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248\u201352.","journal-title":"Clin Pharmacol Ther"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00647-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00647-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00647-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:31:50Z","timestamp":1744194710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00647-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["647"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00647-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"30 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"116"}}